9/27/2023 0 Comments Graphpad prism price![]() No serious adverse events attributable to rituximab were observed. The median remission time was 29 months and follow-up time was 39.5 months. The median time from rituximab to corticosteroid discontinuation was 3.5 months. Rituximab treatment induced remission in all 10 patients with a median time to remission of 2 months. Results: Ten patients with corticosteroid-resistant ( n = 5) or corticosteroid-dependent ( n = 5) idiopathic minimal-change glomerulopathy were treated with rituximab between 20. Methods: Demographic and clinical data were collected and analyzed from all adult patients with native kidney, biopsy-proven, minimal-change glomerulopathy who were administered rituximab between 20 and cared for at the UNC Kidney Center. Here, we describe the clinical course of adults with corticosteroid-dependent or -resistant minimal-change glomerulopathy who received rituximab. Data to support rituximab use in adults with corticosteroid-dependent or resistant minimal-change glomerulopathy are limited. ![]() Although effective in children, corticosteroid treatment in adults is more variable and time to response can be prolonged. Background: Minimal-change glomerulopathy is defined histologically by the presence of normal glomeruli on light microscopy and diffuse podocyte effacement on electron microscopy. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |